CTA Clinical Practices Guidelines 2 — Questions and Answers
Question 1: According to ICH E6(R2) GCP, what is the primary purpose of a monitoring visit?
- To collect data for statistical analysis
- To verify that the trial is conducted in compliance with the protocol and applicable regulations (Correct answer)
- To train site staff on new procedures
- To audit the sponsor's internal processes
Correct answer: To verify that the trial is conducted in compliance with the protocol and applicable regulations
ICH E6(R2) states that monitoring verifies that trial conduct, data recording, and reporting comply with the protocol, SOPs, GCP, and applicable regulatory requirements.
Question 2: Which document defines the acceptable range for a laboratory test value beyond which a clinical trial protocol requires mandatory reporting?
- The informed consent form
- The investigator's brochure
- The protocol or laboratory reference ranges specified therein (Correct answer)
- The case report form completion guidelines
Correct answer: The protocol or laboratory reference ranges specified therein
The protocol specifies clinically significant laboratory ranges and reporting thresholds that sites must follow during the trial.
Question 3: Under GCP, when a protocol deviation occurs at a site, what is the CTA's first responsibility?
- Immediately terminate the subject's participation
- Notify the IRB/IEC before taking any other action
- Document the deviation and report it to the sponsor per the protocol and SOPs (Correct answer)
- Correct the deviation silently to avoid regulatory attention
Correct answer: Document the deviation and report it to the sponsor per the protocol and SOPs
GCP requires that deviations be documented and reported to the sponsor according to the protocol and applicable SOPs so appropriate corrective action can be taken.
Question 4: What is the key distinction between a protocol deviation and a protocol violation in clinical trials?
- Deviations are planned; violations are unplanned
- Violations are minor; deviations are major
- Violations involve unapproved changes to key design elements; deviations are unintended departures that may or may not affect subject safety or data integrity (Correct answer)
- There is no meaningful distinction — the terms are interchangeable
Correct answer: Violations involve unapproved changes to key design elements; deviations are unintended departures that may or may not affect subject safety or data integrity
Violations typically refer to departures that affect subject safety or data integrity, while deviations are unintended non-compliances that may be minor, though terminology varies by sponsor and regulation.
Question 5: Which GCP principle requires that all clinical trial information be recorded, handled, and stored to allow accurate reporting, interpretation, and verification?
- Beneficence
- Data integrity (Correct answer)
- Equipoise
- Randomization
Correct answer: Data integrity
GCP's data integrity principle ensures that trial records are accurate, complete, and verifiable to support regulatory submissions and scientific conclusions.
Question 6: A subject enrolled in a blinded trial inadvertently discovers their treatment assignment. According to GCP, what action is most appropriate?
- Remove the subject immediately without documentation
- Document the unblinding event, notify the investigator and sponsor, and assess impact on data integrity (Correct answer)
- Continue the trial without any action since the subject is already enrolled
- Automatically discontinue the subject and exclude their data
Correct answer: Document the unblinding event, notify the investigator and sponsor, and assess impact on data integrity
Unblinding events must be documented, reported, and assessed for their impact on trial integrity and subject safety per GCP requirements.
Question 7: In Good Clinical Practice, the term 'essential documents' refers to which of the following?
- Documents required only by the FDA
- Documents that individually and collectively permit evaluation of the conduct of the trial and the quality of the data produced (Correct answer)
- The informed consent form and investigator's brochure only
- Financial disclosure forms submitted to the sponsor
Correct answer: Documents that individually and collectively permit evaluation of the conduct of the trial and the quality of the data produced
ICH E6 defines essential documents as those that permit evaluation of trial conduct and data quality, and they must be retained in both investigator and sponsor trial master files.
CTA Clinical Practices Guidelines 2
According to ICH E6(R2) GCP, what is the primary purpose of a monitoring visit?